Elizabeth A. Grimm
Professor
Department of Melanoma Medical Oncology
MD Anderson Cancer Center
United States of America
Biography
Primary Appointment:- Waun Ki Hong Distinguished Chair in Translational Oncology, Department of Melanoma Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Deputy Division Head for Research Affairs, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Professor, Department of Melanoma Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Dual/Joint/Adjunct Appointment: Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Professor, Department of Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, TX.
Research Interest
Cancer biology of intrinsic tumor cytokine expression and other inflammatory mediators, that support tumor growth and apoptosis resistance pathways. This area of research is based on her findings of endogenous constitutive interleukins and iNOS-driven nitric oxide (NO) production in the tumor cells of patients with the worst prognoses; Translational studies directed toward the development of new therapies and validating inflammatory markers for prognosis and prediction of therapy in human melanoma, both cutaneous and uveal.
Publications
-
Tanese K, Grimm EA, Ekmekcioglu S. The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: Its impact on the chemokine expression profile, including suppression of CXCL10. Int J Cancer 131 (4) :891-901, 2012.
-
Chattopadhyay C, Ellerhorst JA, Ekmekcioglu S, Greene VR, Davies MA, Grimm EA. Association of Activated c-Met with NRAS-Mutated Human Melanomas: A Possible Avenue for Targeting. Int J Cancer 131 (2) :E56-65, 2012.
-
Qin Y, Deng W, Ekmekcioglu S, Grimm EA. Identification of unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma by a large-scale synthetic lethal RNAi screening. Pigment Cell Melanoma Res 26 (1) :97-112, 2013.
